Table 3.

TIL characteristics

PatientsResp.Surgery to ACT (d)*TIL age at REP (d)Fold expans.Cells ×109% CD8Total CD8 (×109)IFN-γ (pg/mL)
Responders
05-LACR44191,3606890.66236
19-NSCR232121,0703771.9272,654
03-MGPR83151,1127690.369676
06-TSPR36101,4607079.155No target
09-SD§PR26121,4466955.6387,830
13-BSPR36111,5966881.355No target
14-SV§PR63141,3002622.961,035
16-SHPR43111,5547585.9644,347
18-WRPR481483340208No target
20-TYPR133148223872.327No target
Average74.4 ± 63.613.2 ± 2.61,255 ± 28257.0 ± 18.167.0 ± 26.141.2 ± 23.2
Nonresponders
01-AYSD76227203167.9210
07-ZRSD56201,2006077.847No target
08-RMSD51171,2901850.89No target
12-VS§SD104118334064.2268,955
02-PEPD6921813309428Nonspec.
04-BA§PD8699003964.325116
10-BEPD59159753854210
11-KBPD37231,4367261.4440
15-SM§PD34202301126.63412
17-ZD§PD4228521242.110
Average61.4 ± 22.518.6 ± 5.7892 ± 36136.5 ± 17.556.3 ± 25.922.4 ± 15.4
P = 0.550P = 0.013P = 0.022P = 0.025P = 0.370P = 0.047

Abbreviations: Resp., best objective response according to the RECIST criteria.

  • *Days from the tumor harvest to TIL infusion.

  • % CD8+ cytotoxic T cells in the infusion bag, all the other cells are CD4 T helper cells.

  • IFNγ secretion (pg/mL) after coculture with melanoma cells as target.

  • §Patients with HLA-A*0201.